Monochlonal antibodies targeting CD24 in the treatment of pancreatic cancer

Number of publications: 5
Israeli Partner: N. Arber, Tel-Aviv Sourasky Med. Center
German Partner: P. Altevogt, DKFZ


Bretz, N. P., Salnikov, A. V., Doberstein, K., Garbi, N., Kloess, V., Joumaa, S., Naumov, I., Boon, L., Moldenhauer, G., Arber, N., Altevogt, P.

Lack of CD24 expression in mice reduces the number of leukocytes in the colon 161 (1), Immunol Lett, 140-8, 2014

Reuven, N., Adler, J., Porat, Z., Polonio-Vallon, T., Hofmann, T. G., Shaul, Y.

The Tyrosine Kinase c-Abl Promotes Homeodomain-interacting Protein Kinase 2 (HIPK2) Accumulation and Activation in Response to DNA Damage 290 (27), J Biol Chem, 16478-88, 2015

Shapira, S., Kazanov, D., Weisblatt, S., Starr, A., Arber, N., Kraus, S.

The CD24 protein inducible expression system is an ideal tool to explore the potential of CD24 as an oncogene and a target for immunotherapy in vitro and in vivo 286 (47), J Biol Chem, 40548-55, 2011

Shapira, S., Lisiansky, V., Arber, N., Kraus, S.

Targeted immunotherapy for colorectal cancer: monoclonal antibodies and immunotoxins 19, Expert Opin Investig Drugs, S67-77, 2010

Shapira, S., Shapira, A., Starr, A., Kazanov, D., Kraus, S., Benhar, I., Arber, N.

An immunoconjugate of anti-CD24 and Pseudomonas exotoxin selectively kills human colorectal tumors in mice 140 (3), Gastroenterology, 935-46, 2011

to top